A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
Status:
Completed
Trial end date:
2019-06-24
Target enrollment:
Participant gender:
Summary
This is a Phase 2, double-blind, randomized, placebo-controlled study to assess the effects
of AK002, given monthly for 4 doses. It is hypothesized that AK002 is more effective than
placebo control (alternative hypothesis) in reducing the number of eosinophils per high power
field (HPF) in gastric and/or duodenal biopsies before and after receiving AK002 or placebo
versus no difference between AK002 and placebo control (null hypothesis).